Is there a generic for Ziprasidone mesylate?

Yes. The FDA Orange Book lists 3 approved generic (ANDA) applications for Ziprasidone mesylate, referencing the brand GEODON. Generics rated with an "A" therapeutic-equivalence code are considered substitutable for the brand.

What is the reference-listed drug for Ziprasidone mesylate?

GEODON (NDA 020919, VIATRIS) is the reference-listed drug — the approved product a generic applicant must show its version is the same as.

What dosage forms of Ziprasidone mesylate are approved?

Ziprasidone mesylate is approved in the following dosage form: powder.

FDA Orange Book · active-ingredient family

Ziprasidone mesylate

Ziprasidone mesylate is approved as 1 brand and 3 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:GEODON · NDA 020919

Brand (NDA)

Generics (ANDA)

Listed patents

Exclusivity periods

Brand (NDA) products · powder

Product	Applicant	Application	TE	Approved
GEODONRLD	VIATRIS	NDA 020919	AP	Jun 21, 2002

Generic (ANDA) products (3)

Product	Applicant	Application	TE	Approved
ZIPRASIDONE MESYLATE	STERISCIENCE	ANDA 217595	AP	Sep 03, 2025
ZIPRASIDONE MESYLATE	MSN	ANDA 216091	AP	Sep 15, 2022
ZIPRASIDONE MESYLATE	GLAND	ANDA 211908	AP	Dec 26, 2019

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Ziprasidone mesylate — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo